MedTrace Logo

Community Health Assessment Program in the Philippines (CHAP-P)

NCT03481335 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 5229

Last updated 2021-03-01

No results posted yet for this study

Summary

This study aims to evaluate the effectiveness of the Community Health Assessment Program in the Philippines (CHAP-P), looking at the differences between communities implementing CHAP-P versus communities not implementing CHAP-P.

Conditions

Interventions

OTHER

CHAP-P Sessions

Residents of intervention communities (barangays) aged 40+ are openly invited to attend CHAP-P sessions. At CHAP-P sessions, trained local volunteers (Barangay Health Workers, or BHWs) collect consent, measure blood pressure, collect other physical measurements, and conduct a survey to determine clients' risk of diabetes. Based on the findings, BHWs provide education and/or referrals. CHAP-P sessions are held twice a month, and clients are encouraged to continuing attending for ongoing follow-up and monitoring.

Sponsors & Collaborators

  • Ateneo de Zamboanga University

    collaborator OTHER

  • Université de Montréal

    collaborator OTHER

  • Global Alliance for Chronic Diseases (GACD)

    collaborator OTHER

  • Canadian Institutes of Health Research (CIHR)

    collaborator OTHER_GOV

  • International Development Research Centre, Canada

    collaborator OTHER_GOV

  • McMaster University

    lead OTHER

Principal Investigators

  • Gina Agarwal, MBBS, PhD · McMaster University

  • Fortunato Cristobal, MD, MPH, MHPEd · Ateneo de Zamboanga University

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
40 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2018-06-01
Primary Completion
2019-07-01
Completion
2020-12-31

Countries

  • Philippines

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03481335 on ClinicalTrials.gov